以患者为中心的HIV感染者抗逆转录病毒治疗降阶梯策略
本文讨论在HIV感染者中实施抗逆转录病毒治疗(ART)降阶梯的策略,结合药物负担与患者药物生活体验(PLEM)框架,提出何时、对谁、如何及为何考虑这些策略。现有单 tablet 方案、两药方案和长效治疗为降阶梯提供可能,但整体健康与生活质量获益仍需进一步研究。
要点
- 现代单 tablet、两药及长效方案为ART降阶梯提供可行性。
- PLEM框架有助于以患者为中心精准选择降阶梯策略。
- 降阶梯对整体健康和生活质量的获益尚待进一步验证。
核心结论
- 存在多种安全且病毒学有效的ART降阶梯策略,但其对患者整体健康和生活质量的最终获益仍需进一步探索。
研究设计与样本
- 本文为综述/观点文章,讨论HIV感染者中ART降阶梯策略,未报告系统检索范围或样本量。
主要发现
- 仅少数研究探索了HIV感染者降阶梯的获益,聚焦于停用非抗逆转录病毒共用药或管理药物相互作用。
- 现代单 tablet 方案、两药方案和长效治疗为ART降阶梯讨论提供条件。
- PLEM框架有助于解读降阶梯策略并提供以患者为中心的精准医学方法。
临床怎么用
- 可结合PLEM评估药物负担,个体化考虑ART降阶梯策略。
- 降阶梯决策需权衡病毒学安全性与患者整体健康及生活质量。
局限性
- 仅少数研究探索降阶梯获益,整体健康和生活质量方面的最终获益尚未明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Only a few studies have explored the benefit of deprescribing in people living with HIV (PLWH), focusing on the discontinuation of non-antiretrovirals (non-ARVs) used for HIV-associated comorbidities (co-medications), or the management of drug-drug interactions (DDIs) between ARVs or between ARVs and co-medications. The availability of modern single-tablet regimens, two-drug regimens and long-acting therapy opens a discussion regarding ARV deprescribing strategies. The objective of this article is to discuss ARV deprescribing strategies in the context of medication-related burden and patients' lived experience with medicine (PLEM) and to suggest indications for whom, when, how and why to consider these ARV options in PLWH. A PLEM construct helps to better interpret these strategies and provides a patient-centred precision-medicine approach. There are several safe and virologically effective ARV deprescribing strategies, but the ultimate benefits of these interventions still need to be further explored in terms of the overall health and quality of life of patients.
引用
- Guaraldi G, Milic J, Marcotullio S, et al. A patient-centred approach to deprescribing antiretroviral therapy in people living with HIV. J Antimicrob Chemother. 2020. PMID: 32747939. doi:10.1093/jac/dkaa329
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。